189 related articles for article (PubMed ID: 18026991)
41. The expression and significance of survivin mRNA in urinary bladder carcinomas.
Wang H; Xi X; Kong X; Huang G; Ge G
J Cancer Res Clin Oncol; 2004 Aug; 130(8):487-90. PubMed ID: 15138808
[TBL] [Abstract][Full Text] [Related]
42. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer.
Golijanin D; Shapiro A; Pode D
J Urol; 2000 Dec; 164(6):1922-5. PubMed ID: 11061882
[TBL] [Abstract][Full Text] [Related]
43. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms.
Murphy WM; Rivera-Ramirez I; Medina CA; Wright NJ; Wajsman Z
J Urol; 1997 Dec; 158(6):2102-6. PubMed ID: 9366322
[TBL] [Abstract][Full Text] [Related]
44. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
[TBL] [Abstract][Full Text] [Related]
45. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review.
Ku JH; Godoy G; Amiel GE; Lerner SP
BJU Int; 2012 Sep; 110(5):630-6. PubMed ID: 22353238
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
47. Value of urinary survivin as a diagnostic marker in bladder cancer.
Abd El-Hakim TF; El-Shafie MK; Abdou AG; Azmy RM; El-Naidany SS; Badr El-Din MO
Anal Quant Cytopathol Histpathol; 2014 Jun; 36(3):121-7. PubMed ID: 25141488
[TBL] [Abstract][Full Text] [Related]
48. Clinical experience with survivin as a biomarker for urothelial bladder cancer.
Horstmann M; Bontrup H; Hennenlotter J; Taeger D; Weber A; Pesch B; Feil G; Patschan O; Johnen G; Stenzl A; Brüning T
World J Urol; 2010 Jun; 28(3):399-404. PubMed ID: 20309562
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic role of survivin in urinary bladder cancer.
Srivastava AK; Singh PK; Srivastava K; Singh D; Dalela D; Rath SK; Goel MM; Brahma Bhatt ML
Asian Pac J Cancer Prev; 2013; 14(1):81-5. PubMed ID: 23534808
[TBL] [Abstract][Full Text] [Related]
50. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
52. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis.
Sharp JD; Hausladen DA; Maher MG; Wheeler MA; Altieri DC; Weiss RM
Front Biosci; 2002 Feb; 7():e36-41. PubMed ID: 11815300
[TBL] [Abstract][Full Text] [Related]
53. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
54. THE SIGNIFICANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND SURVIVIN EXPRESSION IN BLADDER CANCER TISSUE AND URINE CYTOLOGY OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER.
Kehinde EO; Al-Maghrebi M; Anim JT; Kapila K; George SS; Al-Juwaiser A; Memon A
East Afr Med J; 2013 Jan; 90(1):19-27. PubMed ID: 26862626
[TBL] [Abstract][Full Text] [Related]
55. Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder.
Hou JQ; He J; Wen DG; Chen ZX; Zeng J
Chin Med J (Engl); 2006 Jul; 119(13):1118-20. PubMed ID: 16834932
[No Abstract] [Full Text] [Related]
56. Multiplex protein signature for the detection of bladder cancer in voided urine samples.
Rosser CJ; Ross S; Chang M; Dai Y; Mengual L; Zhang G; Kim J; Urquidi V; Alcaraz A; Goodison S
J Urol; 2013 Dec; 190(6):2257-62. PubMed ID: 23764080
[TBL] [Abstract][Full Text] [Related]
57. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
58. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.
Brems-Eskildsen AS; Zieger K; Toldbod H; Holcomb C; Higuchi R; Mansilla F; Munksgaard PP; Borre M; Ørntoft TF; Dyrskjøt L
BMC Cancer; 2010 Nov; 10():646. PubMed ID: 21106093
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of urinary HURP mRNA as a marker for detection of bladder cancer: relation to bilharziasis.
Eissa S; Matboli M; Mansour A; Mohamed S; Awad N; Kotb YM
Med Oncol; 2014 Feb; 31(2):804. PubMed ID: 24375315
[TBL] [Abstract][Full Text] [Related]
60. Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma.
Eissa S; Kenawy G; Swellam M; El-Fadle AA; Abd El-Aal AA; El-Ahmady O
Clin Biochem; 2004 Sep; 37(9):803-10. PubMed ID: 15329320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
